← Markets

Labcorp Holdings Inc.

LH · NYSE

Market closed$283.36$1.42 (+0.50%)After hours $283.36 · 0.00%

Key statistics

Previous close$281.94
Open$279.21
Day high$290.65
Day low$279.03
52-week high$293.72
52-week low$241.81
Market cap23.24B
Volume501.79K
Average volume659.45K
P/E ratio16.82
Forward P/E12.05
EPS16.85
Dividend yield+1.02%

Market context

Why it moved

Labcorp (LH) edged higher amid continued institutional buying interest, with both Illinois Municipal Retirement Fund and Bessemer Group significantly boosting their stakes, reinforcing positive Wall Street sentiment supported by the company's strong recent quarterly results and a consensus "Moderate Buy" rating with an average price target well above current levels.

StockinvestMarketbeatHindustantimesPremomFacebook

What is happening

Recent company-specific developments and publisher coverage.

July 16, 2026Labcorp closed up nearly 3.7%, outperforming the broader healthcare sector (XLV), as a broad-based rally swept healthcare stocks led by UnitedHealth Group's strong Q2 earnings beat and Abbott's 42% diagnostics revenue surge following its Exact Sciences acquisition. The $14.5M DOJ False Claims Act settlement announced July 15 — involving historical Medicare billing for its ToxAssure urine drug testing panel — appears to have been absorbed by investors as a contained, manageable liability rather than a material headwind, with Baird and Evercore ISI recently raising price targets to $338 and $315, respectively.

3.6582

July 16, 2026Labcorp closed modestly lower during the regular session but is rebounding sharply in after-hours trading, up nearly 2%, after the DOJ announced a $14.5 million settlement over False Claims Act allegations tied to its ToxAssure Comprehensive urine drug testing panel. Labcorp acknowledged responsibility for certain billing practices involving Medicare from 2018–2023 but emphasized the settlement is limited to this specific test and is not an admission of liability. Separately, Baird recently raised its price target to $338 (from $335) while maintaining an Outperform rating, and the consensus among 19 analysts sits at an average target of ~$312, roughly 13% above the prior close — underscoring continued bullish analyst sentiment despite the legal headline.

-1.3385

July 14, 2026Labcorp closed modestly lower as healthcare sector earnings scrutiny and broader macro crosscurrents weighed on sentiment, though the stock found some support from fresh analyst optimism. Baird raised its price target on Labcorp to $338 from $335, reiterating an Outperform rating, while Evercore ISI lifted its target to $315 earlier in the week — the consensus average target stands near $312, implying meaningful upside. Investors are also watching peer Quest Diagnostics' upcoming Q2 earnings (July 23) and a broader healthcare sector facing a reported 9% Q2 earnings decline, though much of that is driven by accounting distortions at Gilead rather than underlying diagnostics weakness. AI models tracking Labcorp have grown more constructive on improved guidance and cash flow, adding to a positive longer-term narrative even as Iran-driven oil price surges and Fed rate hike risks cloud the near-term macro backdrop.

-0.3614

July 14, 2026Labcorp closed essentially flat amid a broadly risk-off session driven by renewed U.S.-Iran hostilities and surging oil prices, though the stock is slipping further in after-hours trading. The session was bookended by bullish analyst activity: Baird raised its price target to $338 (from $335) while maintaining Outperform, and B of A Securities lifted its target to $320 with a Buy rating — both citing improving guidance and cash flow. AI analyst models have also turned more constructive on the name. With a consensus target of ~$312 and 19 analysts rating it a Buy, sentiment remains positive heading into Q2 earnings season, even as healthcare sector headwinds and macro uncertainty weigh.

-0.047

July 11, 2026Labcorp closed modestly lower, slipping alongside the healthcare sector (XLV) as the diagnostics leader declared its quarterly dividend of $0.72 per share payable September 11 — maintaining its payout unchanged. The dividend announcement provided a steady income signal for investors even as the broader diagnostics space watches M&A activity closely, with peer Qiagen surging 11% on private equity buyout interest and DiaSorin rejecting a Thermo Fisher bid. The XLV healthcare ETF has been reaching record highs amid a broader sector rotation, though Labcorp's below-average trading volume suggests limited conviction in either direction ahead of Q2 earnings season.

-0.2954

July 10, 2026Labcorp Holdings closed essentially flat as investors digested the company's declaration of its quarterly dividend of $0.72 per share, payable September 11. The muted price action belies a constructive backdrop: Labcorp has been rated "Bullish" in recent healthcare sector analyses, is up roughly 14% year-to-date, and analysts peg fair value near $310 — above current levels — supported by the nationwide Medicare-covered rollout of its RNA-based ColoSense colorectal screening test and expanding oncology and liver disease diagnostics. Healthcare has been the market's top-performing sector in recent weeks, with XLV gaining over 6% in June, providing a favorable tailwind even as broader markets navigate US-Iran geopolitical tensions and inflation concerns.

-0.0396

July 9, 2026Labcorp Holdings fell over 2% as a broad market risk-off sell-off swept through equities after President Trump declared the U.S.-Iran ceasefire 'over,' sending oil prices surging more than 5% and stoking fresh inflation fears. Despite the macro headwinds, Labcorp's underlying story remains constructive — the company beat Q1 2026 earnings estimates with EPS of $4.25 vs. $4.12 expected, raised full-year revenue guidance, and has been expanding its diagnostics portfolio with ColoSense, the MyLabcorp AI app, and deeper Epic integration, with analysts maintaining a consensus price target near $310.

-2.156

July 8, 2026Labcorp Holdings closed essentially flat as Evercore ISI raised its price target to $315 from $300, reinforcing the bullish analyst consensus of ~$311 average target. The stock is benefiting from strong healthcare sector rotation — XLV closed near its 52-week high — as investors shift capital from overheated semiconductors into diagnostics and healthcare names. Labcorp's recent momentum is underpinned by a Q1 2026 earnings beat (adj. EPS $4.25 vs. $4.12 est.), raised full-year revenue guidance, and a wave of product launches including the ColoSense colorectal RNA test, expanded DPYD Genotyping, and the AI-powered MyLabcorp app.

-0.1864

Seeking Alpha · July 16, 2026Labcorp Holdings Stock: The Story Has Not Changed Materially (NYSE:LH)marketscreener.com · July 16, 2026Labcorp to Pay $14.5 Million to Settle False Claims Act AllegationsPluang · July 16, 2026Labcorp seen as a steady growth buy with cost c...Clinical Lab Products · July 14, 2026Labcorp Expands Access to Non-Invasive MASH Blood Test Through Online PlatformPR Newswire · July 9, 2026Labcorp Declares Quarterly DividendInvesting.com · May 13, 2026Labcorp CEO Adam Schechter sells $1.5 million in LH sharesPR Newswire · April 30, 2026Labcorp Announces 2026 First Quarter Results; Raises Full Year 2026 GuidancePR Newswire · October 28, 2025Labcorp Announces 2025 Third Quarter Results
Mt Newswire · July 16, 2026Update: Labcorp to Pay $14.5 Million to Settle False Claims Act Allegations
Mt Newswire · July 15, 2026Labcorp to Pay $14.5 Million to Settle False Claims Act Allegations
Benzinga · July 13, 2026B of A Securities Maintains Buy on Labcorp Holdings, Raises Price Target to $320
Benzinga · July 13, 2026Baird Maintains Outperform on Labcorp Holdings, Raises Price Target to $338
Mt Newswire · July 9, 2026Labcorp Keeps Quarterly Dividend at $0.72 a Share, Payable Sept. 11 to Holders of Record Aug. 28
Mt Newswire · July 7, 2026Evercore ISI Adjusts Price Target on Labcorp to $315 From $300
Mt Newswire · June 22, 2026Labcorp Says ColoSense Colorectal Cancer Screening Test Available Nationwide
Benzinga · June 22, 2026Labcorp Announces Nationwide Availability Of ColoSense, Its RNA-Based, At-Home Colorectal Cancer Screening Test

Peers

S&P 500SPX · $7,457.78-1.01%Quest Diagnostics IncorporatedDGX · $210.68+0.61%IQVIA Holdings Inc.IQV · $206.26-2.01%Thermo Fisher Scientific Inc.TMO · $532.48-1.97%Charles River Laboratories International, Inc.CRL · $224.35-2.10%ICON Public Limited CompanyICLR · $170.000.00%Bio-Rad Laboratories, Inc.BIO · $304.36+1.12%DaVita Inc.DVA · $236.97+1.26%Chemed CorporationCHE · $510.03+1.70%BrightSpring Health Services, Inc. Common StockBTSG · $70.69+3.71%Henry Schein, Inc.HSIC · $87.82-0.50%Medpace Holdings, Inc.MEDP · $537.73-0.04%